Genprex

The Acclaim-3 trial completed phase 1 evaluating quaratusugene ozeplasmid with atezolizumab for extensive-stage small cell lung cancer, with no dose-limiting toxicities and an RP2D of 0.12 mg/kg. Phase 2 enrollment has opened, aiming to determine 18-week progression-free survival.

Genprex completed Phase 1 of Acclaim-3 trial, showing REQORSA and Tecentriq safe for ES-SCLC patients. The Safety Review Committee approved Phase 2 expansion, with REQORSA's Recommended Phase 2 Dose set at 0.12 mg/kg. The trial aims to determine 18-week progression-free survival rates.

Genprex completed Phase 1 of Acclaim-3 trial, showing REQORSA and Tecentriq safe for ES-SCLC patients. The Safety Review Committee approved Phase 2 expansion with a recommended dose of 0.12 mg/kg. The trial aims to determine 18-week progression-free survival rates.

Genprex, Inc. completed Phase 1 of Acclaim-3 trial for Reqorsa® Gene Therapy with Tecentriq® in ES-SCLC, proceeding to Phase 2. The Safety Review Committee set the Recommended Phase 2 Dose at 0.12 mg/kg. Genprex anticipates presenting Phase 1 results in 2025 and has a bullish outlook with a $7.50 price target. The company focuses on gene therapy for cancer and diabetes, with Reqorsa® receiving FDA designations for SCLC treatment.

Genprex completed Phase 1 dose escalation of Acclaim-3 trial, showing favorable safety of REQORSA and Tecentriq in ES-SCLC patients. The Safety Review Committee approved the Recommended Phase 2 Dose of 0.12 mg/kg and opened Phase 2 for enrollment. The trial aims to determine 18-week progression-free survival rates.

Genprex, Inc. secures exclusive license from University of Michigan for Reqorsa® Gene Therapy in combination with ALK-inhibitors to treat ALK-positive lung cancer, based on positive preclinical data.

Lung cancer is the leading cause of cancer deaths in both men and women. Kiromic BioPharma’s Deltacel shows disease stabilization in NSCLC patients. Achilles Therapeutics advances EHC in phase 1/2 trials for NSCLC and melanoma. Genprex reports positive results in 2 lung cancer trials for Reqorsa but drops Acclaim-2. CAN-2409 improves survival in NSCLC patients not responding to ICI therapy.